AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
3.00
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close3.00
Open2.99
Bid0.00 x 0
Ask0.00 x 0
Day's range2.92 - 3.07
52-week range0.50 - 4.24
Volume1,899,152
Avg. volume4,141,056
Market cap460.818M
Beta1.22
PE ratio (TTM)N/A
EPS (TTM)-0.62
Earnings date11 May 2017 - 12 May 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.67
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance

    AVEO Oncology today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr.

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks7 days ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • Business Wire9 days ago

    EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)

    EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC) and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for aRCC.i Tivozanib is an oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI). EUSA Pharma is the licensee for tivozanib in Europe, North and South Africa, Latin America and Australasia.

  • Business Wire9 days ago

    EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)

    EUSA Pharma and AVEO Oncology today announced the first commercial launch of FOTIVDA® with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following ...

  • AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
    Zacks16 days ago

    AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

    AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

  • Business Wire16 days ago

    AVEO Oncology to Present at Upcoming Conferences

    AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences:

  • Business Wire17 days ago

    AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update

    AVEO Oncology today reported financial results for the third quarter ended September 30, 2017 and provided a business update.

  • Business Wire18 days ago

    AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA®) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO®), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma (RCC). The results were presented on Friday, November 3, at the 16th International Kidney Cancer Symposium in Miami, in an oral presentation titled “TiNivo: A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma” by Laurence Albiges, M.D., Ph.D., Head, Genitourinary Unit, Institute Gustave Roussy, and a lead investigator of the study.

  • AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma
    Business Wire18 days ago

    AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma

    AVEO Oncology and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb’s nivolumab , an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma .

  • Business Wire18 days ago

    AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA®) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO®), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma (RCC). The results were presented on Friday, November 3, at the 16th International Kidney Cancer Symposium in Miami, in an oral presentation titled “TiNivo: A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma” by Laurence Albiges, M.D., Ph.D., Head, Genitourinary Unit, Institute Gustave Roussy, and a lead investigator of the study.

  • Business Wire18 days ago

    AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma

    AVEO Oncology and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb’s nivolumab , an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma .

  • Business Wirelast month

    AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium

    AVEO Oncology today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami.

  • Business Wire2 months ago

    AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol

    AVEO Oncology today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® to sorafenib in subjects with refractory advanced renal cell carcinoma .

  • Forbes2 months ago

    Two Techs And Two Biotechs Breaking Out

    Here are two biotech and two tech stocks that are breaking out technically.

  • MarketWatch2 months ago

    Harry Boxer’s four stocks that are breaking out this week

    In focus: Amicus Therapeutics, AVEO Pharmaceuticals, AXT and Dynavax Technologies.

  • Business Wire2 months ago

    AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in

    AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the Phase 1/2 TiNivo study. Under terms of the agreement, EUSA may utilize data from the study for regulatory or commercial purposes in exchange for a research and development funding payment totaling $2.0 million. EUSA’s decision follows approval in August of tivozanib by the European Commission for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.

  • Business Wire3 months ago

    AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma

    AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. Tivozanib is indicated for the first line treatment of adult patients with advanced RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.i EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, is the European licensee for tivozanib. Tivozanib is an oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI).

  • Business Wire6 months ago

    AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with first-line renal cell carcinoma (RCC). It is expected that with the oral explanation complete, the CHMP will proceed to an opinion which they will submit to the European Commission (EC), which has the authority to approve medicines for use in the 28 countries in the European Union. “We are pleased that the file continues to progress through the CHMP review process with EUSA having completed an oral explanation for tivozanib,” said Michael Bailey, president and chief executive officer of AVEO.

  • Business Wire7 months ago

    AVEO Reports First Quarter 2017 Financial Results and Provides Business Update

    CAMBRIDGE, Mass.--(BUSINESSWIRE)-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes